glp-1 cardiovascular outcome trials fig1.png Review of Cardiovascular Outcome Trials

Plain Language Summary Obesity is a growing public health issue that increases the risk of developing heart disease, type 2 diabetes, and osteoarthritis

To achieve a GLP-1RA that can act throughout the day, they made modifications and attached a fatty acid chain in the n-terminal that allows binding to albumin [19,20]

All studies adopted the model-based simulation approach using data predominately derived from clinical trials, except for our study, which employed a trial/study-based analysis approach using real-world effectiveness and cost data, to conduct CEA

Bain & Company

[1] [2] Estos medicamentos no estn indicados para el tratamiento de la diabetes tipo 1 ni para la cetoacidosis diabtica

Abbreviations GLP-1: Glucagon-like peptide-1 GLP-1RA: Glucagon-like peptide-1 receptor agonist T2DM: Type-2 diabetes mellitus DPP-4: Dipeptidyl peptidase 4 HbA1c: Hemoglobin A1c NASH: Non-alcoholic steatohepatitis NAFLD: Non-alcoholic fatty liver disease Camp: Cyclic adenosine monophosphate PKA: Protein kinase A EPAC: Exchange protein directly activated by cAMP PI3K: Phosphoinositide 3-kinase PYY: Peptide YY CCK: Cholecystokinin GLUT4: Glucose transporter type 4 mTORC1: Mammalian target of rapamycin complex 1 References Ahrn B (2015) Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes